Publications by authors named "Alfred F Furth"

Claim this Profile
A
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
Alfred F Furth, Sumithra J Mandrekar, Angelina D Tan, Andrea Rau, Sara J Felten

Cancer Chemother Pharmacol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.
Julian R Molina, J Fernando Quevedo, Alfred F Furth, Ronald L Richardson, Horst Zincke

Cancer· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
Christopher E Pelloski, Karla V Ballman, Alfred F Furth, Li Zhang, E Lin

J Clin Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duffy-Santner confidence intervals for the two-stage three-outcome design.
Alfred F Furth, Daniel J Sargent

J Biopharm Stat· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraoperative electron-beam radiotherapy and ureteral obstruction.
Robert C Miller, Michael G Haddock, Ivy A Petersen, Leonard L Gunderson, Alfred F Furth

Int J Radiat Oncol Biol Phys· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.
Nadia N Laack, Paul D Brown, Robert J Ivnik, Alfred F Furth, Karla V Ballman

Int J Radiat Oncol Biol Phys· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Megan M Garrity, Lawrence J Burgart, Michelle R Mahoney, Harold E Windschitl, Muhammad Salim, Alfred F Furth

J Clin Oncol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis